FDA Initiates Class III Recall for Qualgen's Testosterone 200 mg Pellets Over Labeling Errors
Qualgen, LLC initiated a Class III recall (D-0517-2025) for 2,832 vials of Testosterone 200 mg Pellets due to incorrect lot numbers on labels, stemming from a printing error. This nationwide recall, ongoing since June 16, 2025, necessitates immediate action from distributors and healthcare providers to verify product authenticity and ensure patient safety, impacting supply chain integrity for compounded hormone therapies.
FDA Initiates Class III Recall for Qualgen's Testosterone Pellets: Labeling Error Identified
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Qualgen, LLC as Class III, pertaining to their Testosterone 200 mg Pellet product. This recall, identified as D-0517-2025, was initiated on June 16, 2025, and is currently ongoing. The specific product affected is Testosterone 200 mg Pellet, packaged in 1mL amber vials, marked as Rx only and a compounded product. A total of 2,832 amber vials are subject to this action. The core issue driving this recall is a critical labeling error: a printing issue resulted in incorrect lot numbers appearing on the product labels. Specifically, Lot number 1043, with an expiration date of February 10, 2026, is impacted. The product carries NDC 69761-202-01. For procurement directors, this necessitates immediate verification of existing inventory for the specified lot number. Regulatory affairs heads must recognize that even seemingly minor printing errors can trigger significant compliance events, requiring robust quality control protocols for all labeling processes to prevent misidentification and ensure product traceability within the supply chain.
Operational Implications and Nationwide Distribution for Qualgen, LLC
Qualgen, LLC, based in Edmond, Oklahoma, is the firm initiating this recall. The distribution pattern for the affected Testosterone 200 mg Pellet is nationwide within the United States. This broad distribution means that the operational impact extends across numerous distributors, pharmacies, and healthcare providers. As a compounded product, the Testosterone 200 mg Pellet serves a specific niche within hormone therapy, and any disruption can affect patient access and treatment continuity. Supply chain VPs must assess their exposure to Qualgen's products and ensure that their downstream partners are fully aware of the recall and have implemented appropriate quarantine and return procedures. For business development executives evaluating partnerships in the compounded pharmaceuticals sector, this event underscores the imperative of conducting thorough due diligence on a manufacturer's quality management systems, particularly those related to labeling and packaging integrity. The voluntary nature of the recall, firm-initiated by Qualgen, LLC, reflects their responsibility in addressing the issue, but the underlying printing defect points to a need for enhanced internal controls to safeguard product quality and market confidence.
Regulatory Compliance and Risk Mitigation for Compounded Therapies
The FDA's classification of this event as a Class III recall indicates that exposure to the mislabeled product is not likely to cause adverse health consequences. However, the ongoing status of the recall, with its center classification date of July 14, 2025, and report date of July 23, 2025, signifies continued regulatory oversight. For regulatory affairs heads, this situation highlights the FDA's unwavering focus on accurate product labeling as a fundamental component of Good Manufacturing Practices (GMP), even for compounded drugs. Inaccurate lot numbers can impede effective recalls, complicate adverse event reporting, and undermine product traceability, posing indirect risks to patient safety and supply chain integrity. This event serves as a reminder that the regulatory environment for pharmaceutical products, including compounded therapies, remains stringent. Companies must proactively review their quality assurance programs, particularly in packaging and labeling, to mitigate similar risks. While this specific recall is Class III, the broader industry has recently seen higher-severity events, such as Essential Wellness Pharma's Class II recall for sterility issues, reinforcing the constant need for vigilance across all aspects of pharmaceutical manufacturing and distribution.